Participants 158 207 4
first-line treatment of metastatic breast cancer.
Participants 434 500 5
first-line treatment of women with metastatic breast cancer (MBC).
Participants 501 675 7
PATIENTS AND METHODS Women (n=509) with MBC and normal cardiac function were randomized to receive either PLD 50 mg/m2 (every 4 weeks) or doxorubicin 60 mg/m2 (every 3 weeks)
